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IVb are constitutively expressed in all tissues, while classNew Insights
III, Iva, and II are typical of brain tissues and are ex-into Drug Resistance in Cancer pressed only at low levels in other tissues. Class VI
possesses the lowest degree of homology to the others
and is specifically expressed in the hematopoietic com-
partment. In functional terms, the presence of the class
New findings by Kavallaris et al. characterize mecha- III inhibits the assembly of -tubulin subunits promoted
nisms of resistance to epothilones and paclitaxel in by paclitaxel, and the class III-depleted subunits show
cell lines. One significant discovery is a novel tubulin enhanced sensitivity to paclitaxel [7].
point mutation positioned outside the paclitaxel bind- The article by Kavallaris and collaborators published
ing site, which confers a high degree of drug resis- in this issue [8] raises several very important points
tance. concerning drug resistance to antimitotic anticancer
agents that inhibit microtubule dynamics. In this study,
Several antimitotic drugs that disrupt microtubule dy- the authors generated a panel of cells with collateral
namics have been introduced to the arsenal of the che- drug resistance to paclitaxel and sensitivity to Vinca
motherapeutics in the fight against cancer over the last alkaloids through stepwise exposure to increased con-
two decades. Prime examples of this class of anticancer centrations of desoxyepothilone B (dEpoB). Since epothi-
therapeutics are the Vinca alkaloids (vinblastine and vin- lones are not a substrate for P-gp, it was expected that
cristine), which were introduced to treat hematopoietic the drug-resistant cell lines would not overexpress P-gp.
malignancies, and the taxanes (paclitaxel and doce- Moreover, when drug-resistant cell lines are generated
taxel), which are arguably the most effective and clini- through chronic and stepwise increase in exposure to
cally successful agents from the last decade. Taxanes a drug, it is highly unlikely that only a single mechanism
interfere with microtubule dynamics by accelerating the of drug resistance is operating, i.e., several mechanisms
polymerization of tubulin monomers and stabilizing should coexist and be contributing to the drug-resistant
microtubules, whereas Vinca alkaloids, colchicinoids, phenotype. In fact, in this article the authors observed
and combretastatins inhibit tubulin polymerization. that multiple drug-resistance mechanisms were op-
The clinical success of the taxanes has stimulated the erating in the same cells. Drug-resistant cells displayed
search for new molecules with a similar mode of action increased expression at the protein level of the most
and has resulted in the discovery of natural products dynamic class III -tubulin isotype. In a recent paper,
including epothilones A and B from myxobacterium, dis- Nicoletti and coworkers quantified the relative ratio of
codermolide from marine sponge, and eleutherobins/ the tubulin isotypes in a panel of 17 human cancer cells
sarcodictyns from soft coral. Interestingly, it appears [9], wherein a statistically significant increase in the
that these structurally unrelated molecules from diverse class III -tubulin is correlated to an inherent drug-resis-
origins share a common pharmacophore with paclitaxel tant phenotype toward paclitaxel and vincristine. This
[1]. Such a hypothetical pharmacophore was used to finding indicates that it is unlikely that changes in the
model the drug binding site in wild-type and mutant relative amounts of -tubulin isotypes could explain the
tubulins [2]. Although taxanes represent a practical im- collateral sensitivity to Vinca alkaloids exhibited by dEpoB-
provement in the clinical management of solid tumors, resistant cells. Besides the overexpression of the class
these drugs have not solved one of the most important III -tubulin, Kavallaris et al. also noticed increased ex-
clinical problems, drug resistance. Also, patients resis- pression of microtubule associated proteins (MAPs). In-
tant to other chemotherapeutic agents but who initially deed, the increased level of MAP4 could compensate
responded to taxanes often relapse, unfortunately, and for the reduced microtubule stability induced by the
do not respond to these drugs anymore. Several mecha- acquired -tubulin mutation or by the increased levels of
nisms of drug resistance have been reported for pacli- the class III -tubulin. In addition, a couple of important
taxel. Since taxanes are substrates for the P-glycopro- point mutations in the class I -tubulin were found in the
tein efflux pump (P-gp), resistant cells may overexpress dEpoB-resistant cells. A heterozygous point mutation
P-gp, thereby hampering intracellular drug retention [3]. at nucleotide 691, resulting in an alanine to threonine
An alternative means by which taxane resistance occurs substitution at amino acid 231, was observed in all dEpoB-
is by point mutation at the target -tubulin within or near resistant cells. The second heterozygous point mutation
the paclitaxel binding site [4]. A third relevant mecha- at nucleotide 874, substituting a glutamine to glutamic
nism underlying drug resistance is the expression of acid at amino acid 292, was found only in the most
-tubulin isotypes that are less sensitive to paclitaxel stringent conditions of drug exposure. These two muta-
inhibition [5]. In fact, -tubulin is encoded by a large tions are actually translated into the corresponding mu-
multigene family, with the most significant differences tated proteins, as demonstrated by peptide mass finger-
at the carboxyl terminus region. Cleveland and Sullivan printing using MALDI-TOF and ESI-TOF tandem mass
used this region to devise a classification system to analyses. Both mutations are novel and different from
distinguish tubulin isotypes in vertebrates [6]. In hu- those reported previously involving amino acid residues
mans, six possible -tubulin isotypes have been identi- 270, 274, 282, and 364 [2]. A231T mutation resides on the
helix 7 of -tubulin, which is located within the bindingfied and characterized for tissue expression. Class I and
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pocket of a paclitaxel molecule [10], whereas Q292E Universita` Cattolica Sacro Cuore
Romemutation is located in the helix H9 near the M loop. The
mutation at 292 is particularly interesting because it is Italy
located apparently outside of the paclitaxel binding site.
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many of these DBDs. While activation and repressionRNA as a Transcriptional Activator
domains are also well characterized at the level of amino
acid sequence composition and character, structural
studies lag far behind the DBDs, and the precise mecha-
Two recent reports demonstrate that in vivo selection nisms leading to gene activation or repression in many
can isolate novel RNAs that activate transcription cases have not yet been elucidated. Activation domains
when tethered to a gene promoter. This highlights the are thought to be responsible for the recruitment of
structural plasticity that allows RNA to fulfill many coactivators, components of the basal transcription ma-
functions normally carried out by proteins. chinery, or enzymes for chromatin modification (chro-
matin remodeling factors and histone-modifying en-
Eukaryotic transcription factors are modular proteins zymes) [2]. Common targets may be shared between
that are generally comprised of a sequence-specific different transcriptional activators, but many activation
DNA binding domain (DBD) tethered to a transcriptional domains share little sequence homology to one another.
activation (AD) or repression domain (RD). Extensive The chemical biology community has long sought to
structural diversity can be found in the various motifs devise methods to control gene expression by targeting
utilized for both DNA binding and activation/repression. specific DNA sequences with novel peptides, oligo-
DBDs are very well characterized, and numerous high- nucleotides, or small molecules [3–5]. Natural or syn-
resolution structures are now available for zinc finger, thetic DBDs have been tethered to peptides derived
helix-turn-helix, leucine zipper, winged helix, and other from potent viral activators [6–9], and fully synthetic
types of DBDs [1]. The molecular details underlying peptides have been fused to natural DBDs for gene
activation [10, 11]. In another approach, peptide librariesbase-sequence specificity have been unraveled for
